

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 April 2021 (01.04.2021)



(10) International Publication Number
WO 2021/059221 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:

PCT/IB2020/058988

(22) International Filing Date:

25 September 2020 (25.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/907,270 27 September 2019 (27.09.2019) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151-85
Södertälje (SE).

(72) Inventors: **HIRSCH, Ian**; AstraZeneca Pharmaceuticals
LP, One MedImmune Way, Gaithersburg, Maryland 20878
(US). **NEWBOLD, Paul**; AstraZeneca Pharmaceuticals
LP, One MedImmune Way, Gaithersburg, Maryland 20878
(US).

(74) Agent: **NESS, Mark**; MedImmune Limited, Milstein
Building, Granta Park, Cambridge Cambridgeshire CB21
6GH (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BENRALIZUMAB FOR USE IN METHODS OF TREATING LATE-ONSET ASTHMA




FIG. 2

(57) Abstract: Provided herein are methods of treating patients with late-onset asthma or asthma falling within Severe Asthma Research Program (SARP) clinical cluster 3 or 5 comprising administering to the patient a therapeutically effective amount of the anti-interleukin-5 receptor (IL-5R) antibody, benralizumab, or an antigen-binding fragment thereof. Also provided are methods of predicting an enhanced therapeutic response to benralizumab by determining the SARP clinical cluster of the patient's asthma prior to administration.

WO 2021/059221 A1